Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference

Core Insights - Royalty Pharma expects Portfolio Receipts for 2024 to reach approximately $2.8 billion, reflecting a year-over-year growth of about 13% in Royalty Receipts [2][3][7] - The company has deployed around $2.8 billion in capital for royalty transactions in 2024, marking a record year for synthetic royalty deals [2][5] - Royalty Pharma's development-stage pipeline has the potential to generate over $1 billion in new royalties from innovative therapies across various therapeutic categories [2][8] Financial Performance - Preliminary unaudited results indicate that Royalty Pharma anticipates adjusted EBITDA for 2024 to be between $2,560 million and $2,570 million, with Portfolio Cash Flow expected to be approximately $2,450 million to $2,455 million [3][26] - Net cash provided by operating activities is projected to be around $2,760 million to $2,770 million for the full year 2024 [3][26] Capital Deployment and Pipeline - Since 2020, Royalty Pharma has announced transactions totaling approximately $15.5 billion, with significant additions in 2024 including royalties on Voranigo and frexalimab [5][8] - The company is set to benefit from several new product launches in 2025, including Voranigo, Yorvipath, Niktimvo, Rytelo, and Cobenfy [6][7] Upcoming Events - Royalty Pharma will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 6:45 p.m. ET [9]